Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

The role of estrogen receptor in breast cancer outcomes and the effect of exposure history

Award Number: F30CA236199
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 12/13/2018
PERIOD OF PERFORMANCE END DATE: 05/31/2021

Group Awards By:

View Award Description

The role of estrogen receptor in breast cancer outcomes and the effect of exposure history - Project Summary Breast cancer is the most frequently diagnosed cancer and the second leading cause of cancer-related death in women. Over 70% of breast tumors overexpress estrogen receptor (ER), which is a strong prognostic indicator and the most reliable predictor of response to endocrine therapy. ER status is routinely assessed in traditional clinical assays; however, these assays are highly sensitive and suppress the true biological range of ER expression. As a result, a number of clinically important features of ER expression have been overlooked in prior clinical and epidemiological studies. Genomic assays now allow for quantification of ER gene expression, offering greater resolution in measuring level of tumor ER, and digital image analysis can detect spatial heterogeneity of ER protein expression within tumor samples. Both of these features have shown associations with breast cancer survival, though prior studies have been limited by small, homogenous patient populations and limited measures of ER. Critical questions remain in understanding the role of ER in breast cancer outcomes. First, it is unknown whether the relationship between ER and survival varies between black and white women. This is important to understand because black women with ER positive breast cancer demonstrate significantly higher mortality rates than white women, even in randomized clinical trials. Second, we have previously shown that smoking is associated with significantly altered tumor ER gene expression, but the impact of other contemporaneous exposures on ER expression remains unexplored. Understanding how exposures modulate expression is critical to accurate interpretation of ER as a biomarker. We propose to investigate the role of ER heterogeneity in breast cancer outcomes using a population- based sample of 5,000 breast cancer patients, of which approximately half are black women. We hypothesize that increasing ER quantity and spatial homogeneity of expression will be associated with better outcomes, particularly in white women, and that exposure history will affect ER expression. We will test this hypothesis with two specific aims. First, we will estimate the association between quantitative measures of ER and survival, overall and by race. We will quantify ER using protein-based measures, including proportion of ER positive cells and intratumoral heterogeneity of expression, and Ribonucleic acid- (RNA) based measures, including Estrogen Receptor 1 (ESR1) expression and a multigene score reflecting estrogen signaling (luminal score). Second, we will evaluate how exposure history impacts quantitative ER and multigene biomarkers that include ER. We will estimate the association between body mass index, oral contraceptive use, hormone therapy use, alcohol use, and cigarette smoking and protein- and RNA- based measures of quantitative ER. These results will demonstrate how quantitative and spatial ER expression associate with survival outcomes and how contemporaneous exposures drive variability in ER expression in heterogenous breast cancer patient populations.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = -$21,500 )
2023	2021	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Research Manpower	000	3	11/23/2022	NON-COMPETING CONTINUATION	-$21,500
														Subtotal = -$21,500

Issue Date FY: 2021 ( Subtotal = $34,013 )
2021	2021	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Research Manpower	001	3	2/2/2021	NON-COMPETING CONTINUATION	$2,583
2021	2021	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Research Manpower	000	3	11/17/2020	NON-COMPETING CONTINUATION	$45,128
2021	2021	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Research Manpower	002	3	8/25/2021	NON-COMPETING CONTINUATION	-$13,698
														Subtotal = $34,013

Issue Date FY: 2020 ( Subtotal = $49,348 )
2020	2020	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Research Manpower	001	2	2/14/2020	NON-COMPETING CONTINUATION	$504
2020	2020	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Research Manpower	000	2	1/17/2020	NON-COMPETING CONTINUATION	$48,844
														Subtotal = $49,348

Issue Date FY: 2019 ( Subtotal = $37,463 )
2019	2019	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Research Manpower	000	1	12/13/2018	NEW	$37,463
														Subtotal = $37,463

Grand Total All Awards = $99,324

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The role of estrogen receptor in breast cancer outcomes and the effect of exposure history

Award Number: F30CA236199

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 12/13/2018

PERIOD OF PERFORMANCE END DATE: 05/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer